Clinical Trials Directory

Trials / Terminated

TerminatedNCT04844346

Plant Stanol Esters and COVID-19 Vaccination Response

The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Maastricht University Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI has previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effect on the immune system, people with overweight or obesity might benefit from consuming plant stanols prior to receiving the COVID-19 vaccination. The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients. The main study endpoint is vaccination response to a COVID-19 vaccine. Secondary endpoints include amongst others hematological, inflammatory and immunological parameters (e.g. hs-CRP, leukocyte differential count) and metabolic markers (e.g. blood lipid profiles, plasma glucose, serum insulin, HOMA-IR).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPlant stanol mini drinksOat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
DIETARY_SUPPLEMENTPlacebo mini drinksOat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
BIOLOGICALCOVID-19 vaccineFirst dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.

Timeline

Start date
2021-04-22
Primary completion
2022-01-11
Completion
2022-01-11
First posted
2021-04-14
Last updated
2022-03-02

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04844346. Inclusion in this directory is not an endorsement.